EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

Re-Irradiation by Stereotactic Radiotherapy of Brain Metastases in the Case of Local Recurrence

Ruben Touati iD, Vincent Bourbonne iD, Gurvan Dissaux iD, Gaëlle Goasduff, Olivier Pradier, Charles Peltier iD, Romuald Seizeur, Ulrike Schick, François Lucia

Cancers · 03.02.2023 · 15 (3) · 996

DOI: 10.3390/cancers15030996 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Cancers, online erschienen am 03.02.2023. Verfasst von Ruben Touati und 8 weiteren Autor:innen. Beteiligte Einrichtung: Radiation Oncology Department, University Hospital, 29200 Brest, France. Die Arbeit wurde bisher 13-mal zitiert (Crossref) und nennt 39 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Purpose

To evaluate the efficacy and safety of a second course of stereotactic radiotherapy (SRT2) treatment for a local recurrence of brain metastases previously treated with SRT (SRT1), using the Hypofractionated Treatment Effects in the Clinic (HyTEC) reporting standards and the European Society for Radiotherapy and Oncology guidelines.

Methods

From December 2014 to May 2021, 32 patients with 34 brain metastases received salvage SRT2 after failed SRT1. A total dose of 21 to 27 Gy in 3 fractions or 30 Gy in 5 fractions was prescribed to the periphery of the PTV (99% of the prescribed dose covering 99% of the PTV). After SRT2, multiparametric MRI, sometimes combined with 18F-DOPA PET-CT, was performed every 3 months to determine local control (LC) and radionecrosis (RN).

Results

After a median follow-up of 12 months (range: 1–37 months), the crude LC and RN rates were 68% and 12%, respectively, and the median overall survival was 25 months. In a multivariate analysis, the performance of surgery was predictive of a significantly better LC (p = 0.002) and survival benefit (p = 0.04). The volume of a normal brain receiving 5 Gy during SRT2 (p = 0.04), a dose delivered to the PTV in SRT1 (p = 0.003), and concomitant systemic therapy (p = 0.04) were associated with an increased risk of RN.

Conclusion

SRT2 is an effective approach for the local recurrence of BM after initial SRT treatment and is a potential salvage therapy option for well-selected people with a good performance status. Surgery was associated with a higher LC.

Schlagwörter

Stichwörter der Autor:innen

brain metastaseslocal controlradionecrosisre-irradiationstereotactic radiation therapy

Autor:innen und Institutionen

  • Radiation Oncology Department, University Hospital, 29200 Brest, France.
  • LaTIM INSERM UMR 1101, University of Western Brittany, 29200 Brest, France.
  • Neurosurgery Department, University Hospital, 29200 Brest, France.

ORCID-Profile: Ruben Touati, Vincent Bourbonne, Gurvan Dissaux, Charles Peltier

Zitieren

APA

Touati, R., Bourbonne, V., Dissaux, G., Goasduff, G., Pradier, O., Peltier, C., Seizeur, R., Schick, U., & Lucia, F. (2023). Re-Irradiation by Stereotactic Radiotherapy of Brain Metastases in the Case of Local Recurrence. Cancers, 15(3), 996. https://doi.org/10.3390/cancers15030996

Vancouver

Touati R, Bourbonne V, Dissaux G, Goasduff G, Pradier O, Peltier C, et al. Re-Irradiation by Stereotactic Radiotherapy of Brain Metastases in the Case of Local Recurrence. Cancers. 2023;15(3):996. doi:10.3390/cancers15030996

BibTeX
@article{Touati2023,
  author = {Touati, Ruben and Bourbonne, Vincent and Dissaux, Gurvan and Goasduff, Gaëlle and Pradier, Olivier and Peltier, Charles and Seizeur, Romuald and Schick, Ulrike and Lucia, François},
  title = {Re-Irradiation by Stereotactic Radiotherapy of Brain Metastases in the Case of Local Recurrence},
  journal = {Cancers},
  year = {2023},
  volume = {15},
  number = {3},
  pages = {996},
  doi = {10.3390/cancers15030996}
}
Kostenlos starten →